Summary
JNJ Chart
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed at $154.42 in the latest trading session, marking a -0.63% move from the prior day.
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent.
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1
Johnson & Johnson Dividends
 JNJ 23 May 2022 | Other | $1.13 Per Share |
| JNJ 18 Feb 2022 | Other | $1.06 Per Share |
| JNJ 22 Nov 2021 | Other | $1.06 Per Share |
| JNJ 23 Aug 2021 | Other | $1.06 Per Share |
| JNJ 24 May 2021 | Other | $1.06 Per Share |
Johnson & Johnson Earnings
| 31 Dec 2016 Date | | - Cons. EPS | 1.38 EPS |
| 30 Sep 2016 Date | | - Cons. EPS | 1.53 EPS |
| 30 Jun 2016 Date | | - Cons. EPS | 1.43 EPS |
| 31 Mar 2016 Date | | - Cons. EPS | 1.54 EPS |
| 31 Dec 2015 Date | | - Cons. EPS | 1.15 EPS |
| JNJ 23 May 2022 | Other | $1.13 Per Share |
| JNJ 18 Feb 2022 | Other | $1.06 Per Share |
| JNJ 22 Nov 2021 | Other | $1.06 Per Share |
| JNJ 23 Aug 2021 | Other | $1.06 Per Share |
| JNJ 24 May 2021 | Other | $1.06 Per Share |
| 31 Dec 2016 Date | | - Cons. EPS | 1.38 EPS |
| 30 Sep 2016 Date | | - Cons. EPS | 1.53 EPS |
| 30 Jun 2016 Date | | - Cons. EPS | 1.43 EPS |
| 31 Mar 2016 Date | | - Cons. EPS | 1.54 EPS |
| 31 Dec 2015 Date | | - Cons. EPS | 1.15 EPS |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Joaquin Duato CEO | XSGO Exchange | US4781601046 ISIN |
| US Country | 138,100 Employees | 18 Feb 2025 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
Contact Information
